Prognostic significance of nuclear and cytoplasmic expression of metallothioneins as related to proliferative activity in squamous cell carcinomas of oral cavity

Histology and Histopathology

Volumn 23, Issue 7, 2008, Pages 843-851

  Szelachowska, Jolanta ^a   Dziegiel, Piotr ^a   Jelen Krzeszewska, Joanna ^a   Jelen, Michal ^a   Tarkowski, Radoslaw ^a   Wlodarska, Iwona ^a   Spytkowska, Barbara ^b   Gisterek, Iwona ^a   Matkowski, Rafal ^a   Kornafel, Jan ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Wroclaw   (Poland)

Author keywords

Ki 67; Mcm 2; MT; Oral cancer; Squamous cell carcinoma

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

ARTICLE; CELL NUCLEUS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 44449167236     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Apostolova M.D. and Cherian M.G. (2000). Nuclear localization of metallothionein during cell proliferation and differentiation. Cell. Mol. Biol. (Noisy-le-grand) 46, 347-356.
2. Bakka A., Endresen L., Johnsen A.B., Edminson P.D. and Rugstad H.E. (1981). Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol. Appl. Pharmacol. 61, 215-226.
3. Bakka A., Johnsen A.S., Endresen L. and Rugstad H.E. (1982). Radioresistance in cells with high content of metallothionein. Experientia. 38, 381-383.
4. Beenken S.W., Krontiras H., Maddox W.A., Peters G.E., Soong S. and Urist M.M. (1999). T1 and T2 squamous cell carcinoma of the oral tongue: prognostic factors and the role of elective lymph node dissection. Head Neck 21, 124-130.
5. Cai L., Satoh M., Tohyama C. and Cherian M.G. (1999). Metallothionein in radiation exposure: its induction and protective role. Toxicology 132, 85-98
6. Cai L. and Cherian M.G. (2003). Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium- metallothioneins. Toxicol. Lett. 136, 193-198.
7. Cai L., Iskander S., Cherian M.G. and Hammond R.R. (2004). Zinc- or cadmium-pre-induced metallothionein protects human nervous system cells and astrocytes from radiation-induced apoptosis. Toxicol. Lett. 146, 217-226.
8. Cardoso S.V., Barbosa H.M., Candellori I.M., Loyola A.M. and Aguiar M.C. (2002). Prognostic impact of metallothionein on oral squamous cell carcinoma. Virchows Arch. 441, 174-178.
9. Cherian M.G., Jayasurya A. and Bay B.H. (2003). Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res. 533, 201-209.
10. Deng D.X., Cai L., Chakrabarti S. and Cherian M.G. (1999). Increased radiation-induced apoptosis in mouse thymus in the absence of metallothionein. Toxicology 134, 39-49.
11. Dietl B., Schafer C. and Kolbl O. (2005). The prognostic value of time parameters in adjuvant radiotherapy of head and neck cancer. A retrospective analysis of 138 patients. Strahlenther Onkol. 181, 800-807.
12. Douglas-Jones A.G., Schmid K.W., Bier B., Horgan K., Lyons K., Dallimore N.D., Moneypenny I.J. and Jasani B. (1995). Metallothionein expression in duct carcinoma in situ of the breast. Hum. Pathol. 26, 217-222.
13. Dziegiel P., Forgacz J., Suder E., Surowiak P., Kornafel J. and Zabel M. (2003). Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol. Histopathol. 18, 401-407.
14. Dziegiel P. (2004). Expression of metallothioneins in tumor cells. Pol. J. Pathol. 55, 3-12.
15. Dziegiel P. and Zabel M. (2006). Role of immunohistochemical expression of Ki-67 in adenocarcinoma of large intestine. In: Handbook of immunohistochemistry and in situ hybridization of human carcinomas. Volume 4. Hayat M.A. (eds). Elsevier. pp 127-134.
16. Dziegiel P., Salwa-Zurawska W., Zurawski J., Wojnar A. and Zabel M. (2005). Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol. Histopathol. 20, 83-89.
17. Haerslev T., Jacobsen G.K. and Zedeler K. (1995). The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas. APMIS 103, 279-285.
18. Hishikawa Y., Koji T., Dhar D.K., Kinugasa S., Yamaguchi M. and Nagasue N. (1999). Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br. J. Cancer 81, 712-720.
19. Hiura T., Khalid H., Yamashita H., Tokunaga Y., Yasunaga A. and Shibata S. (1998). Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer 83, 2361-2369.
20. Ioachim E., Kamina S., Demou A., Kontostolis M., Lolis D. and Agnantis N.J. (1999). Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res. 19, 2133-2139.
21. Jasani B. and Schmid K.W. (1997). Significance of metallothionein overexpression in human tumours. Histopathology. 31, 211-214.
22. Jayasurya A., Bay B.H., Yap W.M., Tan N.G. and Tan B.K. (2000). Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis 21, 1809-1812.
23. Langendijk J.A., de Jong M.A., Leemans C.R., de Bree R., Smeele L.E., Doornaert P. and Slotman B.J. (2003). Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int. J. Radiat. Oncol. Biol. Phys. 57, 693-700.
24. Lee S.S., Yang S.F., Ho Y.C., Tsai C.H. and Chang Y.C. (2008). The upregulation of metallothionein-1 expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Oncol. 44, 180-186.
25. Leemans C.R., Tiwari R., Nauta J.J., van der Waal I. and Snow G.B. (1994). Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 73, 187-190.
26. Meskel H.H., Cherian M.G., Martinez V.J., Veinot L.A. and Frei J.V. (1993). Metallothionein as an epithelial proliferative compartment marker for DNA flow cytometry. Mod. Pathol. 6, 755-760.
27. Moussa M., Kloth D., Peers G., Cherian M.G., Frei J.V. and Chin J.L. (1997). Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen. Clin. Invest. Med. 20, 371-380.
28. Muramatsu Y., Hasegawa Y., Fukano H., Ogawa T., Namuba M., Mouri K., Fujimoto Y., Matsuura H., Takai Y. and Mori M. (2000). Metallothionein Immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses. Anticancer Res. 20, 257-264.
29. Muriel V.P., Tejada M.R. and de Dios Luna del Castillo J. (2001). Time-dose-response relationships in postoperatively irradiated patients with head and neck squamous cell carcinomas. Radiother Oncol. 60, 137-145.
30. Nagel W.W. and Vallee B.L. (1995). Cell cycle regulation of metallothionein in human colonic cancer cells. Proc. Natl. Acad. Sci USA 92, 579-583.
31. Ofner D., Maier H., Riedmann B., Bammer T., Rumer A., Winde G., Bocker W., Jasani B. and Schmid K.W. (1994). Immuno-histochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival. Virchows Arch. 425, 491-497.
32. Pindborg J.J., Reichart P.A., Smith C.J. and van der Waal I. (1997). Histological typing of cancer and precancer of oral mucosa. Springer-Verlag. Berlin.
33. Podhorska-Okolow M., Dziegiel P., Dolinska-Krajewska B., Dumanska M., Cegielski M., Jethon Z., Rossini K., Carraro U. and Zabel M. (2006). Expression of metallothionein in renal tubules of rats exposed to acute and endurance exercise. Folia Histochem. Cytobiol. 44, 195-200.
34. Remmele W. and Stegner H.E. (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immuno-histochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138-140.
35. Satoh M., Cherian M.G., Imura N. and Shimizu H. (1994). Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res. 54, 5255-5257.
36. Smith D.J., Jaggi M., Zhang W., Galich A., Du C., Sterrett S.P., Smith L.M. and Balaji K.C. (2006). Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology 67, 1341-1347.
37. Sobin L.H. and Wittekind C. (1997). UICC TNM classification of malignant tumours. 5th edition. Springer-Verlag. Berlin.
38. Steel G.G. (1997). Basic clinical radiobiology. Second edition. Oxford University Press, Inc. London.
39. Sundelin K., Jadner M., Norberg-Spaak L., Davidsson A. and Hellquist H.B. (1997). Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur. J. Cancer 33, 1860-1864.
40. Surowiak P., Matkowski R., Materna V., Gyorffy B., Wojnar A., Pudelko M., Dziegiel P., Kornafel J. and Zabel M. (2005). Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance. Histol. Histopathol. 20, 1037-1044.
41. Surowiak P., Materna V., Maciejczyk A., Pudelko M., Markwitz E., Spaczynski M., Dietel M., Zabel M. and Lage H. (2007). Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch. 450, 279-285
42. Szelachowska J., Dziegiel P., Jelen-Krzeszewska J., Jelen M., Matkowski R., Pomiecko A., Spytkowska B., Jagas M., Gisterek I. and Kornafel J. (2006). Mcm-2 protein expression predicts prognosis better than Ki-67 antigen in oral cavity squamocellular carcinoma. Anticancer Res. 26, 2473-2478.
43. Tapiero H. and Tew K.D. (2003) Trace elements in human physiology and pathology: zinc and metallothioneins. Biomed. Pharmacother. 57, 399-411.
44. Warters R.L., Hofer K.G., Harris C.R. and Smith J.M. (1977). Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site of radiation damage. Curr. Top. Radiat. Res. 12, 389-407.